China Tests Centralized Purchases Of Large Devices
This article was originally published in PharmAsia News
China’s Ministry of Health has requested that non-profit health institutes participate in centralized purchases of category A medical devices on a trial basis.
You may also be interested in...
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.